Literature DB >> 18085333

Family history and serology predict Crohn's disease after ileal pouch-anal anastomosis for ulcerative colitis.

Gil Y Melmed1, Phillip R Fleshner, Ovunc Bardakcioglu, Andrew Ippoliti, Eric A Vasiliauskas, Konstantinos A Papadakis, Marla Dubinsky, Carol Landers, Jerome I Rotter, Stephan R Targan.   

Abstract

PURPOSE: Approximately 5 to 10 percent of patients undergoing ileal pouch-anal anastomosis with a diagnosis of ulcerative colitis are subsequently diagnosed with Crohn's disease. Preoperative predictors for Crohn's disease post-ileal pouch-anal anastomosis have not been prospectively defined.
METHODS: A total of 238 consecutive patients with ulcerative colitis or indeterminate colitis undergoing ileal pouch-anal anastomosis were prospectively enrolled into a longitudinal database. Clinical factors were assessed perioperatively. Serum drawn preoperatively was assayed for anti-Saccharomyces cerevisiae, antiouter membrane porin-C, anti-CBir1, and perinuclear antineutrophil cytoplasmic antibody using enzyme-linked immunosorbent assay. Crohn's disease was defined by small bowel inflammation proximal to the ileal pouch or a perianal fistula identified at least three months after ileostomy closure. Predictors were assessed in a multivariate Cox proportional hazards model to predict the rate of Crohn's disease after ileostomy closure.
RESULTS: Sixteen patients (7 percent) were diagnosed with Crohn's disease; median time to Crohn's disease was 19 (range, 1-41) months. Significant factors for postoperative Crohn's disease after ileal pouch-anal anastomosis included family history of Crohn's disease (hazard ratio, 8.4; 95 percent confidence interval, 2.96-24.1; P < 0.0001) and anti-Saccharomyces cerevisiae immunoglobulin-A seropositivity (hazard ratio, 3.14; 95 percent confidence interval, 1.1-9.81; P = 0.04). Crohn's disease developed in only 8 of 198 patients (4 percent) without these predictors vs. 8 of 40 patients (20 percent) in those with at least one of these factors (P = 0.002). The cumulative risk of Crohn's disease among patients with two risk factors (67 percent) was higher than in patients with either risk factor (18 percent) or neither risk factor (4 percent, P < 0.001).
CONCLUSIONS: Patients with ulcerative colitis and indeterminate colitis with a family history of Crohn's disease or preoperative anti-Saccharomyces cerevisiae immunoglobulin-A seropositivity are more likely to be diagnosed with Crohn's disease after ileal pouch-anal anastomosis.

Entities:  

Mesh:

Year:  2007        PMID: 18085333      PMCID: PMC2442922          DOI: 10.1007/s10350-007-9158-3

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  50 in total

1.  A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease.

Authors:  A Saxon; F Shanahan; C Landers; T Ganz; S Targan
Journal:  J Allergy Clin Immunol       Date:  1990-08       Impact factor: 10.793

2.  Results of the pelvic-pouch procedure in patients with Crohn's disease.

Authors:  A A Deutsch; R S McLeod; J Cullen; Z Cohen
Journal:  Dis Colon Rectum       Date:  1991-06       Impact factor: 4.585

3.  Overlap in the spectrum of non-specific inflammatory bowel disease--'colitis indeterminate'.

Authors:  A B Price
Journal:  J Clin Pathol       Date:  1978-06       Impact factor: 3.411

4.  Infliximab therapy in pediatric Crohn's pouchitis.

Authors:  Koorosh Kooros; Aubrey J Katz
Journal:  Inflamm Bowel Dis       Date:  2004-07       Impact factor: 5.325

5.  Serum antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease are mainly associated with ulcerative colitis. A correlation study between perinuclear antineutrophil cytoplasmic autoantibodies and clinical parameters, medical, and surgical treatment.

Authors:  M Oudkerk Pool; P M Ellerbroek; B U Ridwan; R Goldschmeding; B M von Blomberg; A S Peña; K M Dolman; H Bril; W Dekker; J J Nauta
Journal:  Gut       Date:  1993-01       Impact factor: 23.059

6.  Consequences of ileal pouch-anal anastomosis for Crohn's colitis.

Authors:  N H Hyman; V W Fazio; W B Tuckson; I C Lavery
Journal:  Dis Colon Rectum       Date:  1991-08       Impact factor: 4.585

7.  Indeterminate colitis predisposes to perineal complications after ileal pouch-anal anastomosis.

Authors:  W A Koltun; D J Schoetz; P L Roberts; J J Murray; J A Coller; M C Veidenheimer
Journal:  Dis Colon Rectum       Date:  1991-10       Impact factor: 4.585

8.  Rediversion after ileal pouch-anal anastomosis. Causes of failures and predictors of subsequent pouch salvage.

Authors:  E F Foley; D J Schoetz; P L Roberts; P W Marcello; J J Murray; J A Coller; M C Veidenheimer
Journal:  Dis Colon Rectum       Date:  1995-08       Impact factor: 4.585

9.  Ileal pouch-anal anastomoses complications and function in 1005 patients.

Authors:  V W Fazio; Y Ziv; J M Church; J R Oakley; I C Lavery; J W Milsom; T K Schroeder
Journal:  Ann Surg       Date:  1995-08       Impact factor: 12.969

10.  Effect of proctocolectomy on serum antineutrophil cytoplasmic antibodies in patients with chronic ulcerative colitis.

Authors:  P Aitola; A Miettinen; A Mattila; M Matikainen; E Soppi
Journal:  J Clin Pathol       Date:  1995-07       Impact factor: 3.411

View more
  30 in total

1.  Current and future role of serogenomics in ulcerative colitis.

Authors:  Mark H Flasar; Raymond K Cross; David B Doman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-11

2.  Pre-colectomy appendectomy and risk for Crohn's disease in patients with ileal pouch-anal anastomosis.

Authors:  Zhaoxiu Liu; Haiyan Lu; Ravi P Kiran; Runzhou Ni; Feza H Remzi; Bo Shen
Journal:  J Gastrointest Surg       Date:  2012-04-24       Impact factor: 3.452

3.  Utility of fecal and serum anti-Saccharomyces cerevisiae antibodies in the diagnosis of Crohn's disease-like condition of the pouch.

Authors:  Linda Y Tang; Hui Cai; Udayakumar Navaneethan; James H Boone; Sarah J Rhodes; Lauren Moore; Hyunjin Rho; Carol de La Motte; Elaine Queener; Bo Shen
Journal:  Int J Colorectal Dis       Date:  2012-03-20       Impact factor: 2.571

4.  Serologic and laboratory markers in prediction of the disease course in inflammatory bowel disease.

Authors:  Marla Cindy Dubinsky
Journal:  World J Gastroenterol       Date:  2010-06-07       Impact factor: 5.742

5.  Infliximab to Treat Refractory Inflammation After Pelvic Pouch Surgery for Ulcerative Colitis.

Authors:  Orlaith B Kelly; Morgan Rosenberg; Andrea D Tyler; Joanne M Stempak; A Hillary Steinhart; Zane Cohen; Gordon R Greenberg; Mark S Silverberg
Journal:  J Crohns Colitis       Date:  2015-12-30       Impact factor: 9.071

Review 6.  Diagnosis and management of pouchitis and ileoanal pouch dysfunction.

Authors:  Udayakumar Navaneethan; Bo Shen
Journal:  Curr Gastroenterol Rep       Date:  2010-12

Review 7.  The status of diagnostic markers for inflammatory bowel disease.

Authors:  Poonam Beniwal; Laura Harrell
Journal:  Curr Gastroenterol Rep       Date:  2010-12

8.  ASCA IgG and CBir antibodies are associated with the development of Crohn's disease and fistulae following ileal pouch-anal anastomosis.

Authors:  Jennifer A Coukos; Lauren A Howard; Janice M Weinberg; James M Becker; Arthur F Stucchi; Francis A Farraye
Journal:  Dig Dis Sci       Date:  2012-02-07       Impact factor: 3.199

9.  Serologic markers associated with development of Crohn's disease after ileal pouch anal anastomosis for ulcerative colitis.

Authors:  Brindusa Truta; Dan X Li; Uma Mahadevan; Elena R Fisher; Yunn-Y Chen; Kim Grace; Fernando Velayos; Jonathan P Terdiman
Journal:  Dig Dis Sci       Date:  2013-10-04       Impact factor: 3.199

Review 10.  Diagnostic advances in inflammatory bowel disease (imaging and laboratory).

Authors:  Maria E Moscandrew; Edward V Loftus
Journal:  Curr Gastroenterol Rep       Date:  2009-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.